Title Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor- activating mutation-positive non-small-cell lung cancer patients
نویسندگان
چکیده
Objective: To compare the effectiveness and costeffectiveness of erlotinib versus gefitinib as first-line treatment of epidermal growth factor receptor– activating mutation-positive non–small-cell lung cancer patients. Design: Indirect treatment comparison and a costeffectiveness assessment.
منابع مشابه
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
OBJECTIVE To compare the effectiveness and cost-effectiveness of erlotinib versus gefitinib as first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients. DESIGN. Indirect treatment comparison and a cost-effectiveness assessment. SETTING Hong Kong. PATIENTS Those having epidermal growth factor receptor-activating mutation-positi...
متن کاملCost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors.
To the Editor—I read with great interest, in the recent issue of the Hong Kong Medical Journal, the article “Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non–small-cell lung cancer patients in Hong Kong” by Lee et al.1 The authors, by indirect treatment comparison, demonstrated the cos...
متن کاملAssessment of epidermal growth factor receptor status in glioblastomas
Objective(s): Our previous study showed that a newly designed tracer radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline ([125I]PYK) is promising for the evaluation of the epidermal growth factor receptor (EGFR) status and prediction of gefitinib treatment of non-small cell lung cancer. EGFR is over-expressed and mutated also in glioblastoma. In the present study, the ...
متن کاملClinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
OBJECTIVE Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with non-small cell lung cancer. Although the safety profile of these drugs is favorable, a small proportion of patients with EGFR mutation-positive non-small cell lung cance...
متن کاملCombination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with activating mutations in the EGFR gene. However, resistance to the EGFR TKIs develops mostly secondary to T790M mutation in exon 20. The use of afatinib associated with cetuximab represents a new possibility of therapy following pro...
متن کامل